Literature DB >> 32763531

Cognitive impairment in chronic ketamine abusers.

Chenxi Zhang1, Yan Xu1, Bin Zhang1, Wei Hao2, Wai Kwong Tang3.   

Abstract

BACKGROUND: The treatment of ketamine users is substantially challenged by high dropout rates, raising questions regarding contributing factors. A number of studies have highlighted the potential of greater focus on the clinical significance of cognitive impairments in ketamine users. The present study hypothesized that cognitive deficits would play a role in greater risk for treatment dropout in chronic ketamine users.
METHODS: Our study examined cognitive performance in the form of working memory, verbal memory, visual memory and executive function among chronic ketamine users who completed three-month treatment in residential detoxification centres (N = 165), those who dropped out prematurely (N = 121) and drug-free healthy controls (N = 111). The data collection was completed in Hong Kong among the East Asia population.
RESULTS: Compared to healthy controls, cognitive impairments were found in ketamine users, including in verbal/visual memory and executive function. Executive dysfunction was significantly associated with dropout in ketamine users within three months.
CONCLUSION: Our findings suggest that executive dysfunction may have clinical benefits in ketamine users admitted to residential treatment programmes.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognitive impairment; Dropout; Executive functioning; Ketamine; Retention

Mesh:

Substances:

Year:  2020        PMID: 32763531     DOI: 10.1016/j.psychres.2020.113206

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

1.  Test-retest reliability and cross-cultural applicability of DSM-5 adopted diagnostic criteria for ketamine use disorders.

Authors:  Nicole D Fitzgerald; Catherine W Striley; Joseph J Palamar; Jan Copeland; Steven Kurtz; Linda B Cottler
Journal:  Drug Alcohol Depend       Date:  2021-09-21       Impact factor: 4.492

Review 2.  Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine.

Authors:  Jeffrey J Mojica; Eric S Schwenk; Clinton Lauritsen; Stephanie J Nahas
Journal:  Curr Pain Headache Rep       Date:  2021-12-11

3.  Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users.

Authors:  Qiuxia Wu; Jinsong Tang; Chang Qi; An Xie; Jianbin Liu; Joseph O'Neill; Tieqiao Liu; Wei Hao; Yanhui Liao
Journal:  J Psychiatry Neurosci       Date:  2022-07-26       Impact factor: 5.699

4.  Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997-2019.

Authors:  John Martin Corkery; Wan-Chu Hung; Hugh Claridge; Christine Goodair; Caroline S Copeland; Fabrizio Schifano
Journal:  J Psychopharmacol       Date:  2021-06-05       Impact factor: 4.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.